Are you aware that MS is associated with a high risk of DVTs and pulmonary embolus? #ClinicSpeak #MSBlog #MSResearch
"Only a month ago a husband of one of my patients with SPMS phoned to say that his wife had died suddenly of a pulmonary embolus (PE). He was surprised that they hadn't been warned about this risk. It made me realise that maybe we should have a system in place to inform all of our patients of the risk of DVT & PE and give then generic advice on how to prevent, or at least reduce the chances, of this potentially fatal complication of MS from happening."
"To try and lower your risk and help prevent DVT, take these steps:
- Maintain an active lifestyle with regular exercise - daily, if possible. Walking, swimming and cycling, activities that activate the muscles in the calf, that pump the blood to the heart, are appropriate activities.
- Try and maintain a healthy weight - obesity increases your risks of DVT and PE.
- If you smoke, stop. Smoking is another risk factor for thrombosis.
- Report any family or personal history of blood-clotting problems to your MS team.
- Discuss alternatives to birth control pills, or hormone-replacement therapy, with your MS team or GP; these therapies increase your chances of having a DVT.
- Making sure you don't get dehydrated; this is something MSers do, in particular those who have troubling bladder problems."
"If you need surgery, you may need specific measures to help prevent DVT; for example having the surgery under local, rather than general, anesthetic, taking an anticoagulant, wearing a calf device on your legs during surgery to compress your legs and keep blood flowing through your veins, wearing elastic compression stockings, elevating the foot of your bed, becoming mobile ASAP after surgery, taking analgesics to make it easier to move around, doing regular leg exercises such as leg lifts and gentle foot and ankle exercises."
"If you have to travel or sit still for long periods of time your risk of DVT increases. The following may help reduce this risk: wearing compression stockings, avoiding wearing short, tight socks, avoid crossing your legs for long periods, drinking plenty of fluids and avoid dehydrating fluids, such as alcohol, if possible get up and walk around every hour or do regular leg exercises such as leg lifts and gentle foot and ankle exercises. Some guidelines recommend taking a low dose of aspirin (150mg) before travelling, in particular on long-haul flights, but this advice is controversial."
"It is important that if you have any symptoms suggestive of a DVT or PE you should seek urgent medical attention. Some cases of DVT may be asymptomatic, however, possible symptoms include:
- pain, swelling and tenderness in one of your legs (usually the calf)
- a heavy ache in the affected area
- warm skin in the area of the clot
- redness of your skin, particularly at the back of your leg below the knee
- breathlessness, which may develop gradually or come on very suddenly
- chest pain, which is typically made worse when you breathe in
- sudden collapse
"As DVT is a new topic on this blog, I would appreciate it if you could take a few seconds to complete this survey."
Epub: Roshanisefat et al. Multiple sclerosis clinical course and cardiovascular disease risk - Swedish cohort study. Eur J Neurol. 2014 Jul 17.
BACKGROUND AND PURPOSE: Cardiovascular disease (CVD) risk amongst MSers appears raised, but few studies have examined CVD risk amongst an unselected MSer group. MS course may be relevant for CVD risk. Our aim was to assess CVD risk and variation by course in MSers.
METHODS: The Multiple Sclerosis Register identified 7667 MSers who received an MS diagnosis between 1964 and 2005. They were matched by age, period, region and sex with 76 045 members of the general population without MS using Swedish registers. Poisson regression compared the two cohorts to estimate the relative risk for CVD, overall, as well as grouped and individual CVD diagnoses.
RESULTS: MSers had an increased adjusted relative risk (with 95% confidence intervals; number of MS cohort events) for CVD of 1.31 (1.22-1.41; n = 847), with some variation by course: relapsing-remitting 1.38 (1.17-1.62; n = 168); secondary progressive 1.30 (1.18-1.53; n = 405) and primary progressive 1.15 (0.93-1.41; n = 108). The association for the relapsing-remitting course was not significant after excluding the first year of follow-up. Overall incidence rates per 1000 person-years for CVD are 11.8 (11.06-12.66) for the MS cohort and 8.8 (8.60-9.05) for the non-MS cohort. The most pronounced association was for deep vein thrombosis: relapsing-remitting 2.16 (1.21-3.87; n = 14), secondary progressive 3.41 (2.45-4.75; n = 52) and primary progressive 3.57 (1.95-6.56; n = 15). MS was associated with ischaemic stroke but largely during the first year of follow-up. MS was associated with a decreased relative risk for angina pectoris and atrial fibrillation.
CONCLUSIONS: There is a significantly increased relative risk for CVD in MS, particularly for venous thromboembolic disorders in progressive MS, suggesting immobility as a possible factor. An increased frequency of ischaemic stroke in MS is most probably due to surveillance bias resulting from diagnostic investigations for MS. There is no increased relative risk for ischaemic heart disease in MS and atrial fibrillation appears to be less common than amongst the general population.